📰 Peter Borchmann News
Peter Borchmann News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Peter Borchmann. Real-time updates on events, politics, business and more.
June 1, 2024
OSAKA, Japan & CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Jun 1, 2024--
June 1, 2024
An Adcetris-based treatment regimen improved progression-free survival and was more tolerable for patients with classical Hodgkin lymphoma.
June 1, 2024
Four-year progression-free survival outcomes revealed the BrECADD regimen was superior to the eBEACOPP regimen, and BrECADD had a promising benefit-risk profile.
June 1, 2024
Better efficacy with brentuximab vedotin versus standard chemo, substantially less toxicity
June 22, 2023
The BrECADD combination had noninferior efficacy and superior tolerability compared with escalated BEACOPP in patients with advanced classical Hodgkin lymphoma, according to data from the phase 3 HD21 trial.
June 20, 2023
– Results are from 1,500 patient trial conducted by German Hodgkin Study Group to test ADCETRIS regimen versus international standard eBEACOPP therapy – ADCETRIS regimen showed less... | June 20, 2023